Stockreport

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update [Yahoo! Finance]

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable safety profile Completed an oversubscribed $160 million PIPE financing led by lea [Read more]